Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination
We report the usefulness of adding the IL-10:IL-6 ratio in order to potentially reveal more aggressive lymphomas: either a transformation or an association with another “hidden” lymphoma such as primary CNS lymphoma (PCNSL). (Source: Seminars in Hematology)
Source: Seminars in Hematology - July 6, 2017 Category: Hematology Authors: Myrto Costopoulos, Rathana Kim, Sylvain Choquet, Karim Maloum, Caroline Houillier, Caroline Algrin, Catherine Settegrana, Juliette Villemonteix, Martine Brissard, Claire Quiney, Sophie Bernard, Frederic Davi, Catherine Thieblemont, Khe Hoang-Xuan, Veroniq Source Type: research
CSF IL-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination
Identifying the etiology of neurological symptoms in blood malignancies is still a challenging issue. Lymphomatous meningitis (LM) is mainly described in aggressive systemic lymphomas (diffuse large B-cell (DLBCL) and Burkitt lymphomas) [1,2]. Leptomeningeal involvement in small B-cell lymphoproliferative disorders (CLPD) is a rare, poorly described condition, only mentioned in a few case-reports [3,4]. The diagnosis is suspected in patients presenting non-specific central nervous system (CNS) symptoms and non-specific results on medical imaging. (Source: Seminars in Hematology)
Source: Seminars in Hematology - July 6, 2017 Category: Hematology Authors: Myrto Costopoulos, Rathana Kim, Sylvain Choquet, Karim Maloum, Caroline Houillier, Caroline Algrin, Catherine Settegrana, Juliette Villemonteix, Martine Brissard, Claire Quiney, Sophie Bernard, Frederic Davi, Catherine Thieblemont, Khe Hoang-Xuan, Veroniq Source Type: research
Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor- β superfamily inhibitors
Patients with lower-risk myelodysplastic syndromes (MDS) are mainly affected by chronic anemia and fatigue. Treatment strategies aim to improve anemia and quality of life, as well as iron overload due to red blood cell transfusion support. To promote proliferation and differentiation of erythropoiesis, erythropoiesis-stimulating agents (ESAs) such as erythropoietin (EPO) and mimetics are applied as first-line therapy in a large fraction of lower-risk MDS patients. In general, ESAs yield favorable responses in about half of the patients, although responses are often short-lived. (Source: Seminars in Hematology)
Source: Seminars in Hematology - July 4, 2017 Category: Hematology Authors: Anna Mies, Uwe Platzbecker Source Type: research
Increasing the effectiveness of hematopoiesis in MDS: Erythropoiesis stimulating agents and TGF- β superfamily inhibitors
Patients with lower risk myelodysplastic syndromes (MDS) are mainly affected by chronic anemia and fatigue. Treatment strategies aim to improve anemia and quality of life as well as iron overload due to red blood cell transfusion support. To promote proliferation and differentiation of erythropoiesis, erythropoiesis stimulating agents (ESAs) such as erythropoietin and mimetics are applied as first-line therapy in a large fraction of lower risk MDS patients. In general, ESAs yield favorable responses in about half of the patients although responses are often short-lived. (Source: Seminars in Hematology)
Source: Seminars in Hematology - July 4, 2017 Category: Hematology Authors: Anna Mies, Uwe Platzbecker Source Type: research
outside front cover, PMS 8883 metallic AND 4/C
(Source: Seminars in Hematology)
Source: Seminars in Hematology - July 1, 2017 Category: Hematology Source Type: research
Masthead
(Source: Seminars in Hematology)
Source: Seminars in Hematology - July 1, 2017 Category: Hematology Source Type: research
table of contents
(Source: Seminars in Hematology)
Source: Seminars in Hematology - July 1, 2017 Category: Hematology Source Type: research
Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders that have a substantial impact on patients ’ quality of life, in addition to causing significant morbidity and mortality. The hypomethylating agents (HMAs) azacitidine and decitabine are approved for use in the United States and in Europe for the treatment of MDS or acute myeloid leukemia (AML) and, in the case of azacitidine, prolong surv ival in higher-risk patients. Neither is curative, though, and given the lack of clear treatment guidelines after HMA treatment failure, it is imperative to optimize patient selection ...
Source: Seminars in Hematology - June 22, 2017 Category: Hematology Authors: Yazan Madanat, Mikkael A. Sekeres Source Type: research
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
Myelodysplastic syndrome (MDS) with deletion 5q (del(5q)) is a distinct clinical and pathological disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion-dependent anemia. Although lenalidomide has erythropoeitic promoting activity in MDS without del(5q) (non-del(5q) MDS), the frequency of response to treatment is lower and relates to biologically separate drug effects. In del(5q) MDS, lenalidomide suppresses the malignant clone to restore effective erythropoiesis by virtue of synthetic lethality, arising from cereblon-dependent degradation of haplodeficient proteins enc...
Source: Seminars in Hematology - June 22, 2017 Category: Hematology Authors: Chetasi Talati, David Sallman, Alan List Source Type: research
Optimizing the use of hypomethylating agents in MDS: Selecting the candidate, predicting the response and enhancing the activityOptimizing HMAs in MDS
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders that have substantial impact on patients ’ quality of life, in addition to causing significant morbidity and mortality. The hypomethylating agents (HMAs) azacitidine and decitabine are approved for use in the United States and in Europe for the treatment of MDS or acute myeloid leukemia and, in the case of azacitidine, prolong survival i n higher-risk patients. Neither is curative, though, and given the lack of clear treatment guidelines after HMA treatment failure, it is imperative to optimize patient selection and iden...
Source: Seminars in Hematology - June 22, 2017 Category: Hematology Authors: Yazan Madanat, Mikkael A. Sekeres Source Type: research
Lenalidomide: MDS with Del(5q) and Beyond
Myelodysplastic syndrome (MDS) with deletion 5q (del(5q)) is a distinct clinical and pathological disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion-dependent anemia. Although lenalidomide has erythropoeitic promoting activity in MDS without del(5q) (non-del(5q) MDS), the frequency of response to treatment is lower and relates to biologically separate drug effects. In del(5q) MDS, lenalidomide suppresses the malignant clone to restore effective erythropoiesis by virtue of synthetic lethality, arising from cereblon-dependent degradation of haplodeficient proteins enc...
Source: Seminars in Hematology - June 22, 2017 Category: Hematology Authors: Chetasi Talati, David Sallman, Alan List Source Type: research
Maximizing the benefit of allogeneic stem cell transplantation in myelodysplastic syndromes
Allogeneic stem cell transplantation (AHSCT) is an evolving field in the treatment of patients with myelodysplastic syndrome (MDS) and has become the third most frequent indication for AHSCT worldwide. Less toxic conditioning regimens, as well as extension of the donor pool to include haplo-identical donors, have led to a broader utility of AHSCT, especially in older patients with MDS. While disease-specific scoring systems such as the International Prognostic Scoring System (IPSS), IPSS-Revised (IPSS-R), or World Health Organization (WHO) Prognostic Scoring System (WPSS) have been used to select patients for AHSCT, new tr...
Source: Seminars in Hematology - June 21, 2017 Category: Hematology Authors: Nicolaus Kr öger Source Type: research
Maximizing the benefit of allogeneic stem cell transplantation in MDS
Allogeneic stem cell transplantation (AHSCT) is an evolving field in the treatment of patients with myelodysplastic syndrome (MDS) and has become the third most frequent indication for AHSCT worldwide. Less toxic conditioning regimen as well as extension of the donor pool including haplo-identical donors have led to a broader utility of AHSCT, especially in older patients with MDS. While disease-specific scoring systems such as IPSS, IPSS-revised or WPSS have been used to select patients for AHSCT, new transplant-specific scoring systems have been developed to determine outcome after AHSCT, which include also transplant- a...
Source: Seminars in Hematology - June 21, 2017 Category: Hematology Authors: Nicolaus Kr öger Tags: SI: 54/3 Therapies in MDS Source Type: research
GATA2 Deficiency and Related Myeloid Neoplasms
The GATA2 gene codes for a hematopoietic transcription factor that through its two zinc fingers (ZF) can occupy GATA-DNA-motifs in a countless number of genes. It is crucial for the proliferation and maintenance of hematopoietic stem cells. During the past five years, germline heterozygous mutations in GATA2 were reported in several hundred patients with various phenotypes ranging from mild cytopenia to severe immunodeficiency involving B, NK, CD4+ cells, monocytes and dendritic cells (MonoMAC/DCML), and myeloid neoplasia. (Source: Seminars in Hematology)
Source: Seminars in Hematology - May 9, 2017 Category: Hematology Authors: Marcin Wlodarski, Matthew Collin, Marshall Horwitz Source Type: research
